Emergent Biosolutions Inc’s recently made public that its Officer COLEEN GLESSNER acquired Company’s shares for reported $0.31 million on Oct 07 ’25. In the deal valued at $10.00 per share,30,608 shares were bought.
Then, Zoon Kathryn C sold 7,086 shares, generating $62,853 in total proceeds. Upon selling the shares at $8.87, the Director now owns 71,799 shares.
Before that, KATHRYN ZOON bought 7,086 shares. Emergent Biosolutions Inc shares valued at $62,853 were divested by the Director at a price of $8.87 per share.
H.C. Wainwright initiated its Emergent Biosolutions Inc [EBS] rating to a Buy in a research note published on December 30, 2024; the price target was $15. A number of analysts have revised their coverage, including Rodman & Renshaw’s analysts, who began to cover the stock in late August with a ‘”a Buy”‘ rating. The Benchmark Company also remained covering EBS and has increased its forecast on March 07, 2024 with a “Buy” recommendation from previously “Hold” rating.
Price Performance Review of EBS
On Monday, Emergent Biosolutions Inc [NYSE:EBS] saw its stock jump 2.54% to $9.3. Over the last five days, the stock has gained 1.75%. Emergent Biosolutions Inc shares have risen nearly 4.14% since the year began. Nevertheless, the stocks have fallen -2.72% over the past one year.
How much short interest is there in Emergent Biosolutions Inc?
A steep rise in short interest was recorded in Emergent Biosolutions Inc stocks on 2025-09-30, growing by 0.9 million shares to a total of 9.61 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 8.71 million shares. There was a rise of 9.33%, which implies that there is a positive sentiment for the stock.
